A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement (ILR7)
Primary Purpose
Unilateral Cataract Extraction, Congenital Cataract
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
OMS302
Phenylephrine HCl
Sponsored by

About this trial
This is an interventional treatment trial for Unilateral Cataract Extraction focused on measuring Cataract, Lens replacement, pediatric
Eligibility Criteria
Inclusion Criteria:
- Are 0 through three years of age at the time of surgery.
- Are to undergo unilateral primary cataract extraction with or without lens replacement.
- Have informed consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization provided by a parent or legal guardian in accordance with local regulations and governing IRB/IEC requirements prior to any procedures or evaluations performed specifically for the sole purpose of this study.
- A parent or legal guardian has indicated that they understand and are able, willing, and likely to fully comply with study procedures and restrictions.
Exclusion Criteria:
- Corneal diameter less than nine millimeters in the study eye.
- Hypersensitivity to phenylephrine, ketorolac, or other NSAIDs, including aspirin, or latex.
- Surgeon's expectation that the protocol-specified mydriatic regimen will not be adequate to perform the procedure and that additional mydriatic treatment (pharmacological or mechanical) will be required.
- Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the Investigator.
- Presence of active or suspected viral, bacterial, or fungal disease in the study eye.
- Use of any topical medication in the study eye within seven days prior to surgery, except for medications needed to examine the eye or prepare for surgery.
- Have a post-traumatic cataract.
- History of uveitis or evidence of past uveitis such as synechiae or keratic precipitates in the study eye.
- Have an ocular neoplasm in the study eye.
- Have a clinically significant infection.
- Have suspected permanent or low vision in the fellow non-study eye, unless caused by a cataract. The study eye must not be the subject's only good eye.
- Use of systemic corticosteroids or NSAIDs in the seven days prior to surgery.
- Have a history of clinically significant corticosteroid-induced intraocular pressure increase.
- Use of any medication for ocular hypertension or glaucoma in the study eye.
- Use of monoamine oxidase inhibitors for 21 days preoperatively.
- Prior participation in a clinical study of OMS302.
- Participating in any investigational drug or device trial within the 30 days prior to the day of surgery.
- History of intraocular non-laser surgery in the study eye within the three months prior to the day of surgery, or intraocular laser surgery in the study eye within 30 days prior to the day of surgery.
- Presence of any condition that the Investigator believes would put the subject at risk or confound the interpretation of the study data.
- Be a member of the immediate family of the Investigator or employees of the investigative site. Immediate family is defined as the Investigator's or employees' natural or legally adopted child (including a stepchild living in the Investigator's household), or grandchild.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
OMS302
Phenylephrine HCl
Arm Description
OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
Outcomes
Primary Outcome Measures
Intraoperative Pupil Diameter
Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm/min) During Surgery Excluding Subjects with In-evaluable Videos.
Acute Postoperative Pain
Mean AUC Analysis of Postoperative pain as measured using the Alder Hey Triage Pain Score at 3, 6, 9, and 24 hours after surgery. The primary analysis of Alder Hey Triage Pain Score was similar to the primary analysis of the change in pupil diameter using AUC. The Alder Hey Triage Pain Score identifies five categories of observations: voice/cry, facial expression, posture, movement, and color. Each of these has a possible score of 0, 1, or 2, resulting in a total score ranging between 0 and 10. A total score of zero means the subject experienced no pain, as the 5 categories added up totals zero. A total score of 10 means the subject experienced a lot of pain and is the worst possible outcome, as the 5 categories added up totals 10.
Parent responses in a diary with a score of 0, 1, or 2.
Cry or voice, 0=no compliant/cry, 1=Consolable, 2=Inconsolable
Facial Expression, 0=Normal, 1=Short grimace <50% of time, 2=Long grimace >50% of time
Posture, 0=Normal, 1=Touching/rub
Safety as Measured by Treatment-emergent Adverse Events, the Number of Affected Patients/at Risk (%) and the Number of Events.
Safety as assessed by the incidence of adverse events and serious adverse events up until the last visit at Day 90.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02132312
Brief Title
A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
Acronym
ILR7
Official Title
A Randomized, Double-Masked, Parallel-Group, Phenylephrine-Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
September 12, 2016 (Actual)
Study Completion Date
September 12, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Omeros Corporation
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effect of OMS302 compared to phenylephrine when administered in irrigation solution during cataract extraction on intraoperative pupil diameter, acute postoperative pain, and safety in children birth through 3 years.
Detailed Description
This study is a randomized, parallel-group, double-masked, phenylephrine-controlled study of OMS302 in young children ages birth through three years undergoing unilateral cataract extraction with or without lens replacement. Administration of test irrigation solutions will take place in a double-masked fashion.
Intraoperative pupil size will be determined by measurement of pupil diameter from still photos captured from video recordings of the procedure. Pupil diameter measurements will be performed immediately prior to the initial incision and at one-minute intervals until the end of the procedure (wound closure). Pain will be assessed by the Alder Hey Triage Pain Score.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Unilateral Cataract Extraction, Congenital Cataract
Keywords
Cataract, Lens replacement, pediatric
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
78 (Actual)
8. Arms, Groups, and Interventions
Arm Title
OMS302
Arm Type
Experimental
Arm Description
OMS302 diluted in balanced salt solution (BSS) and administered as irrigation solution
Arm Title
Phenylephrine HCl
Arm Type
Active Comparator
Arm Description
Phenylephrine diluted in balanced salt solution (BSS) and administered as irrigation solution
Intervention Type
Drug
Intervention Name(s)
OMS302
Intervention Type
Drug
Intervention Name(s)
Phenylephrine HCl
Primary Outcome Measure Information:
Title
Intraoperative Pupil Diameter
Description
Mean Area-under-the-Curve (AUC) Analysis of Change From Baseline in Pupil Diameter (mm/min) During Surgery Excluding Subjects with In-evaluable Videos.
Time Frame
From surgery baseline (pre-incision) through surgery end (time of cortical clean-up/wound closure), the mean time of surgery duration is 35.46 minutes with a standard deviation of 19.98.
Title
Acute Postoperative Pain
Description
Mean AUC Analysis of Postoperative pain as measured using the Alder Hey Triage Pain Score at 3, 6, 9, and 24 hours after surgery. The primary analysis of Alder Hey Triage Pain Score was similar to the primary analysis of the change in pupil diameter using AUC. The Alder Hey Triage Pain Score identifies five categories of observations: voice/cry, facial expression, posture, movement, and color. Each of these has a possible score of 0, 1, or 2, resulting in a total score ranging between 0 and 10. A total score of zero means the subject experienced no pain, as the 5 categories added up totals zero. A total score of 10 means the subject experienced a lot of pain and is the worst possible outcome, as the 5 categories added up totals 10.
Parent responses in a diary with a score of 0, 1, or 2.
Cry or voice, 0=no compliant/cry, 1=Consolable, 2=Inconsolable
Facial Expression, 0=Normal, 1=Short grimace <50% of time, 2=Long grimace >50% of time
Posture, 0=Normal, 1=Touching/rub
Time Frame
24 hours
Title
Safety as Measured by Treatment-emergent Adverse Events, the Number of Affected Patients/at Risk (%) and the Number of Events.
Description
Safety as assessed by the incidence of adverse events and serious adverse events up until the last visit at Day 90.
Time Frame
90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
47 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Are 0 through three years of age at the time of surgery.
Are to undergo unilateral primary cataract extraction with or without lens replacement.
Have informed consent and Health Insurance Portability and Accountability Act (HIPAA) Authorization provided by a parent or legal guardian in accordance with local regulations and governing IRB/IEC requirements prior to any procedures or evaluations performed specifically for the sole purpose of this study.
A parent or legal guardian has indicated that they understand and are able, willing, and likely to fully comply with study procedures and restrictions.
Exclusion Criteria:
Corneal diameter less than nine millimeters in the study eye.
Hypersensitivity to phenylephrine, ketorolac, or other NSAIDs, including aspirin, or latex.
Surgeon's expectation that the protocol-specified mydriatic regimen will not be adequate to perform the procedure and that additional mydriatic treatment (pharmacological or mechanical) will be required.
Presence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, endocrine, neurological, psychiatric, respiratory, or other medical condition that could increase the risk to the subject as determined by the Investigator.
Presence of active or suspected viral, bacterial, or fungal disease in the study eye.
Use of any topical medication in the study eye within seven days prior to surgery, except for medications needed to examine the eye or prepare for surgery.
Have a post-traumatic cataract.
History of uveitis or evidence of past uveitis such as synechiae or keratic precipitates in the study eye.
Have an ocular neoplasm in the study eye.
Have a clinically significant infection.
Have suspected permanent or low vision in the fellow non-study eye, unless caused by a cataract. The study eye must not be the subject's only good eye.
Use of systemic corticosteroids or NSAIDs in the seven days prior to surgery.
Have a history of clinically significant corticosteroid-induced intraocular pressure increase.
Use of any medication for ocular hypertension or glaucoma in the study eye.
Use of monoamine oxidase inhibitors for 21 days preoperatively.
Prior participation in a clinical study of OMS302.
Participating in any investigational drug or device trial within the 30 days prior to the day of surgery.
History of intraocular non-laser surgery in the study eye within the three months prior to the day of surgery, or intraocular laser surgery in the study eye within 30 days prior to the day of surgery.
Presence of any condition that the Investigator believes would put the subject at risk or confound the interpretation of the study data.
Be a member of the immediate family of the Investigator or employees of the investigative site. Immediate family is defined as the Investigator's or employees' natural or legally adopted child (including a stepchild living in the Investigator's household), or grandchild.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Steve Whitaker, MD
Organizational Affiliation
Omeros Corporation
Official's Role
Study Director
Facility Information:
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66103
Country
United States
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
City
Charleston
State/Province
North Carolina
ZIP/Postal Code
29425
Country
United States
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
32221151
Citation
Wilson ME, Trivedi RH, Plager DA. Safety and efficacy data supporting U.S. FDA approval of intracameral phenylephrine and ketorolac 1.0%/0.3% for pediatric cataract surgery: clinical safety and pupil and pain management. J Cataract Refract Surg. 2020 Jun;46(6):873-878. doi: 10.1097/j.jcrs.0000000000000194.
Results Reference
background
Learn more about this trial
A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
We'll reach out to this number within 24 hrs